Brief: Organovo Affirms Key Clinical Development Goals, Reports Fiscal Third-Quarter 2019 Results

VivoSim Labs

07/02/2019 21:20

Feb 7 (Reuters) - Organovo Holdings Inc  ONVO.O :
    * ORGANOVO AFFIRMS KEY CLINICAL DEVELOPMENT GOALS; COMPANY
REPORTS
FISCAL THIRD-QUARTER 2019 RESULTS
    * Q3 REVENUE $800,000 VERSUS REFINITIV IBES ESTIMATE OF
$846,000
    * PRE-INVESTIGATIONAL NEW DRUG  MEETING WITH FDA EXPECTED TO
BE
HELD IN CALENDAR 2019
    * PLANS TO BEGIN IND-ENABLING TOXICITY STUDY FOR ITS LEAD
PROGRAM
IN SECOND HALF OF CALENDAR 2019.

Source text for Eikon:  ID:nGNX1yNMP4 
Further company coverage:  ONVO.O 

 ((Reuters.Briefs@thomsonreuters.com;))